PRESENTATION
FULL-YEAR RESULTS 2020
ANALYST CALL
3 MARCH 2021, 2:00 PM CET
FULL-YEAR RESULTS 2020
SPEAKERS
STEFAN SCHULZE
CHIEF EXECUTIVE OFFICER
COLIN BOND
CHIEF FINANCIAL OFFICER
BUSINESS UPDATE AND OUTLOOK
STEFAN SCHULZE, CHIEF EXECUTIVE OFFICER
2020 HIGHLIGHTS
KEY MILESTONES ACHIEVED ACROSS ALL AREAS
AFFIRM-AHF study of Ferinject® positive readout
KALM-2 phase-III study of KORSUVATM 1 positive readout
CLINICAL TRIALS
INNO2VATE phase-III study of vadadustat2 positive readout
ACCOLADE phase-II study of avacopan3 readout
Recruitment in the phase-II study of VIT-2763 in beta-thalassemia started
MARKET ACCESS
Ferinject® launched in Japan
China: Ferinject® and Veltassa® partnered & NDA submission accepted for Ferinject®
Avacopan3 filing accepted for review in Europe
KORSUVATM 1 filed in the US
BUSINESS DEVELOPMENT
In-licensing agreement with Cara Therapeutics for KORSUVATM 1 extended
Worldwide rights4 of ANG-3777 licensed from Angion Biomedica
Divestment of OM Pharma strengthens focus on key therapeutic areas
1) Licensed from Cara Therapeutics, Inc. 2) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to the US dialysis market 3) Licensed from ChemoCentryx, Inc. 4) Excluding China, Taiwan, Hong Kong and Macau; for all nephrology indications and congestive heart-failure
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Vifor Pharma Ltd. published this content on 03 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2021 11:29:07 UTC.